These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
202 related articles for article (PubMed ID: 12019146)
1. Selective loss of heterozygosity in multiple breast cancers from a carrier of mutations in both BRCA1 and BRCA2. Bell DW; Erban J; Sgroi DC; Haber DA Cancer Res; 2002 May; 62(10):2741-3. PubMed ID: 12019146 [TBL] [Abstract][Full Text] [Related]
2. BRCA1 and BRCA2 mutation status and tumor characteristics in male breast cancer: a population-based study in Italy. Ottini L; Masala G; D'Amico C; Mancini B; Saieva C; Aceto G; Gestri D; Vezzosi V; Falchetti M; De Marco M; Paglierani M; Cama A; Bianchi S; Mariani-Costantini R; Palli D Cancer Res; 2003 Jan; 63(2):342-7. PubMed ID: 12543786 [TBL] [Abstract][Full Text] [Related]
4. The rate of the founder Jewish mutations in BRCA1 and BRCA2 in prostate cancer patients in Israel. Vazina A; Baniel J; Yaacobi Y; Shtriker A; Engelstein D; Leibovitz I; Zehavi M; Sidi AA; Ramon Y; Tischler T; Livne PM; Friedman E Br J Cancer; 2000 Aug; 83(4):463-6. PubMed ID: 10945492 [TBL] [Abstract][Full Text] [Related]
5. Heterogenic loss of the wild-type BRCA allele in human breast tumorigenesis. King TA; Li W; Brogi E; Yee CJ; Gemignani ML; Olvera N; Levine DA; Norton L; Robson ME; Offit K; Borgen PI; Boyd J Ann Surg Oncol; 2007 Sep; 14(9):2510-8. PubMed ID: 17597348 [TBL] [Abstract][Full Text] [Related]
6. Ashkenazi founder BRCA1/BRCA2 mutations in Slovak hereditary breast and/or ovarian cancer families. Cierniková S; Tomka M; Kovác M; Stevurková V; Zajac V Neoplasma; 2006; 53(2):97-102. PubMed ID: 16575464 [TBL] [Abstract][Full Text] [Related]
7. Coinheritance of BRCA1 and BRCA2 mutations with Fanconi anemia and Bloom syndrome mutations in Ashkenazi Jewish population: possible role in risk modification for cancer development. Koren-Michowitz M; Friedman E; Gershoni-Baruch R; Brok-Simoni F; Patael Y; Rechavi G; Amariglio N Am J Hematol; 2005 Mar; 78(3):203-6. PubMed ID: 15726604 [TBL] [Abstract][Full Text] [Related]
8. Concomitant BRCA1 and BRCA2 gene mutations in an Ashkenazi Jewish woman with primary breast and ovarian cancer. Spannuth WA; Thaker PH; Sood AK Am J Obstet Gynecol; 2007 Apr; 196(4):e6-9. PubMed ID: 17403394 [TBL] [Abstract][Full Text] [Related]
9. Novel somatic mutations in the BRCA1 gene in sporadic breast tumors. Janatova M; Zikan M; Dundr P; Matous B; Pohlreich P Hum Mutat; 2005 Mar; 25(3):319. PubMed ID: 15712267 [TBL] [Abstract][Full Text] [Related]
10. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations. Satagopan JM; Boyd J; Kauff ND; Robson M; Scheuer L; Narod S; Offit K Clin Cancer Res; 2002 Dec; 8(12):3776-81. PubMed ID: 12473589 [TBL] [Abstract][Full Text] [Related]
11. Founder mutations in BRCA1/2 are not frequent in Canadian Ashkenazi Jewish men with prostate cancer. Hamel N; Kotar K; Foulkes WD BMC Med Genet; 2003 Aug; 4():7. PubMed ID: 12911837 [TBL] [Abstract][Full Text] [Related]
12. High incidence of BRCA1-2 germline mutations, previous breast cancer and familial cancer history in Jewish patients with uterine serous papillary carcinoma. Biron-Shental T; Drucker L; Altaras M; Bernheim J; Fishman A Eur J Surg Oncol; 2006 Dec; 32(10):1097-100. PubMed ID: 16650962 [TBL] [Abstract][Full Text] [Related]
13. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations. Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145 [TBL] [Abstract][Full Text] [Related]
14. Distinct somatic genetic changes associated with tumor progression in carriers of BRCA1 and BRCA2 germ-line mutations. Tirkkonen M; Johannsson O; Agnarsson BA; Olsson H; Ingvarsson S; Karhu R; Tanner M; Isola J; Barkardottir RB; Borg A; Kallioniemi OP Cancer Res; 1997 Apr; 57(7):1222-7. PubMed ID: 9102202 [TBL] [Abstract][Full Text] [Related]
15. Frequent somatic loss of BRCA1 in breast tumours from BRCA2 germ-line mutation carriers and vice versa. Staff S; Isola JJ; Johannsson O; Borg A; Tanner MM Br J Cancer; 2001 Oct; 85(8):1201-5. PubMed ID: 11710835 [TBL] [Abstract][Full Text] [Related]
16. Germline mutations in the BRCA1 gene predisposing to breast and ovarian cancers in Upper Silesia population. Grzybowska E; Siemińska M; Zientek H; Kalinowska E; Michalska J; Utracka-Hutka B; Rogozińska-Szczepka J; Kaźmierczak-Maciejewska M Acta Biochim Pol; 2002; 49(2):351-6. PubMed ID: 12362976 [TBL] [Abstract][Full Text] [Related]
17. Risk of endometrial carcinoma associated with BRCA mutation. Levine DA; Lin O; Barakat RR; Robson ME; McDermott D; Cohen L; Satagopan J; Offit K; Boyd J Gynecol Oncol; 2001 Mar; 80(3):395-8. PubMed ID: 11263938 [TBL] [Abstract][Full Text] [Related]
18. Germline mutations in the BRCA1 and BRCA2 genes in Turkish breast/ovarian cancer patients. Manguoglu AE; Lüleci G; Ozçelik T; Colak T; Schayek H; Akaydin M; Friedman E Hum Mutat; 2003 Apr; 21(4):444-5. PubMed ID: 12655560 [TBL] [Abstract][Full Text] [Related]
19. Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1. Lose F; Duffy DL; Kay GF; Kedda MA; Spurdle AB; ; J Natl Cancer Inst; 2008 Nov; 100(21):1519-29. PubMed ID: 18957670 [TBL] [Abstract][Full Text] [Related]
20. Incidence of BRCA1 and BRCA2 mutations in 54 Chilean families with breast/ovarian cancer, genotype-phenotype correlations. Gallardo M; Silva A; Rubio L; Alvarez C; Torrealba C; Salinas M; Tapia T; Faundez P; Palma L; Riccio ME; Paredes H; Rodriguez M; Cruz A; Rousseau C; King MC; Camus M; Alvarez M; Carvallo P Breast Cancer Res Treat; 2006 Jan; 95(1):81-7. PubMed ID: 16261400 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]